Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study

Frontiers in Microbiology

Microbiology

Keyu Chen¹  Chuan Jiang¹  Da Cheng¹  Shifang Peng¹  Wenting Peng¹  Huimin Gu¹  Jinqing Liu¹  Cichun Wu¹  Lei Fu² 

[1] Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China;orcid.org/0001-7550-1254;

关键词: hepatitis B virus;    acute-on-chronic liver failure;    tenofovir alafenamide;    kidney function;    efficacy;   

DOI  :  10.3389/fmicb.2023.1185492

 received in 2023-03-13, accepted in 2023-05-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background and aimsReal-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited. Hence, we evaluated the efficacy and kidney safety of TAF among this population.MethodsA total of 272 HBV-related ACLF patients hospitalized at Xiangya Hospital of Central South University were enrolled in this retrospective research. All patients received antiviral therapy with TAF (n = 100) or ETV (n = 172) and comprehensive medical treatments.ResultsThrough 1:1 propensity score matching, 100 patients were finally included in each group. At week 48, the survival rates without transplantation of the TAF group and ETV group were 76.00 and 58.00%, separately (P = 0.007). After 4 weeks of treatment, the TAF treatment group exhibited a significantly decline in HBV DNA viral load (P = 0.029). The mean estimated glomerular filtration rate was apparently improved in the TAF group compared with the ETV group (TAF 5.98 ± 14.46 vs. ETV 1.18 ± 18.07 ml/min/1.73 m2) (P < 0.05). There were 6 patients in TAF group and 21 patients in ETV group with chronic kidney disease (CKD) stage progression ≥ 1. By contrast, the ETV treatment group has a greater risk of renal function progression in CKD 1 stage patients (P < 0.05).ConclusionThis real-world clinical study showed that TAF is more effective than ETV in reducing viral load and improving survival rate in HBV-ACLF patients and the risk of renal function decline is lower.Clinical trial registrationhttps://ClinicalTrials.gov, identifier NCT05453448.

【 授权许可】

Unknown   
Copyright © 2023 Peng, Gu, Cheng, Chen, Wu, Jiang, Liu, Peng and Fu.